- Cell-based therapeutics developer ReNeuron said it expected to report preliminary data from a key clinical trial next month.

The trial was for a human retinal progenitor cell therapy candidate for the blindness-causing disease retinitis pigmentosa, and aimed to evaluate its safety, tolerability and preliminary efficacy.

Dosing of a third cohort of three subjects in the Phase 2a element of the study was complete, and dosing of the remaining cohort was underway.

'We expect to report preliminary data next month from all treated Phase 2a subjects at the American Academy of Ophthalmology 2019 Annual Meeting in San Francisco, which is being held on 12-15 October 2019,' the company said.

'These results will form the basis of our future interactions with the regulatory authorities in Europe and the US regarding the future clinical development path of hRPC for the treatment of retinitis pigmentosa.'

At 8:32am: [LON:RENE] ReNeuron Group PLC share price was -2.5p at 197.5p

Story provided by